AstraZeneca's Tagrisso gets China OK
for type of lung cancer
Send a link to a friend
[September 04, 2019]
(Reuters) - AstraZeneca Plc said on
Wednesday it had received marketing authorization from China's National
Medical Products Administration for its top-selling drug, Tagrisso, to
treat adults with a form of lung cancer.
|
China approved Tagrisso as a first-line treatment for adults with
non-small cell lung cancer patients whose tumors have certain
genetic mutations, AstraZeneca said.
Last month, the British drugmaker said a late-stage study showed
Tagrisso had significantly helped patients with epidermal growth
factor receptor-mutated metastatic non-small cell lung cancer live
longer.
The company has moved deeper into cancer therapy through
wide-ranging deals, including those for immunotherapy and targeted
therapy. Earlier this year, it agreed to a multi-billion dollar
oncology deal with Japan's Daiichi Sankyo Co.
Sales from AstraZeneca's oncology unit soared 57% to $2.17 billion
in the second quarter, accounting for 38% of total product sales,
with revenue from Tagrisso nearly doubling to $784 million.
[to top of second column] |
![](http://archives.lincolndailynews.com/2019/Sep/04/images/ads/current/stclara_lda_SPONSOR_112018.png)
AstraZeneca had also raised its product sales forecast for 2019,
thanks in part to strong sales of cancer drugs.
(The story corrects to show study in August points to overall
survival and not progression free survival in third paragraph.)
(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Bernard
Orr)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |